Back to results
US 2002/0172693 A1Published application
Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
OwnerMichell Anthony DeLong, John McMillan McIver +1inventors
InventorsMichell Anthony DeLong, John McMillan McIver, Robert Scott Youngquist
Life of this patent
Estimating the term…
Abstract
A method for treating hair loss in mammals uses compositions containing prostaglandin F analogs. The compositions can be applied topically to the skin. The compositions can arrest hair loss, reverse hair loss, and promote hair growth.
Claims32
A composition for treating hair loss comprising:
- A) an active ingredient selected from the group consisting of a prostaglandin F analog having a structure selected from the group consisting of
- 111
- pharmaceutically acceptable salts and hydrates of the structures above;
- biohydrolyzable amides, esters, and imides of the structures above;
- optical isomers, diastereomers, and enantiomers of the structures above;
- and combinations thereof;
- wherein R1 is selected from the group consisting of C(O)OH, C(O)NHOH, C(O)OR3, CH2OH, S(O)2R3, C(O)NHR3, C(O)NHS(O)2R4, tetrazole, a cationic salt moiety, a pharmaceutically acceptable amine or ester comprising 2 to 13 carbon atoms, and a biometabolizable amine or ester comprising 2 to 13 atoms;
- R2 is selected from the group consisting of a hydrogen atom, a lower heterogenous group, and a lower monovalent hydrocarbon group;
- R3 is selected from the group consisting of a monovalent hydrocarbon group, a heterogeneous group, a carbocyclic group, a heterocyclic group, an aromatic group, a heteroaromatic group, a substituted monovalent hydrocarbon group, a substituted heterogeneous group, a substituted carbocyclic group, a substituted heterocyclic group, a substituted aromatic group, and a substituted heteroaromatic group;
- R4 is selected from the group consisting of a monovalent hydrocarbon group, a heterogeneous group, a carbocyclic group, a heterocyclic group, an aromatic group, a heteroaromatic group, a substituted monovalent hydrocarbon group, a substituted heterogeneous group, a substituted carbocyclic group, a substituted heterocyclic group, a substituted aromatic group, and a substituted heteroaromatic group;
- X is selected from the group consisting of —C≡C—, a covalent bond, —CH═C═CH—, —CH═CH—, —CH═N—, —C(O)—, —C(O)Y—, —(CH2)n—, wherein n is 2 to 4, —CH2NH—, —CH2S—, and —CH2O—;
- Y is selected from the group consisting of an oxygen atom, a sulfur atom, and NH;
- and
- Z is selected from the group consisting of a carbocyclic group, a heterocyclic group, an aromatic group, a heteroaromatic group, a substituted carbocyclic group, a substituted heterocyclic group, a substituted aromatic group, and a substituted heteroaromatic group;
- and
- B) a carrier.
13 more elements
A method of treating hair loss comprising administering to a mammal a composition comprising:
- A) an active ingredient selected from the group consisting of a prostaglandin F analog having a structure selected from the group consisting of
- 112
- pharmaceutically acceptable salts and hydrates of the structures above;
- biohydrolyzable amides, esters, and imides of the structures above;
- optical isomers, diastereomers, and enantiomers of the structures above;
- and combinations thereof;
- wherein R1 is selected from the group consisting of C(O)OH, C(O)NHOH, C(O)OR3, CH2OH, S(O)2R3, C(O)NHR3, C(O)NHS(O)2R4, tetrazole, a cationic salt moiety, a pharmaceutically acceptable amine or ester comprising 2 to 13 carbon atoms, and a biometabolizable amine or ester comprising 2 to 13 atoms;
- R2 is selected from the group consisting of a hydrogen atom, a lower heterogenous group, and a lower monovalent hydrocarbon group;
- R3 is selected from the group consisting of a monovalent hydrocarbon group, a heterogeneous group, a carbocyclic group, a heterocyclic group, an aromatic group, a heteroaromatic group, a substituted monovalent hydrocarbon group, a substituted heterogeneous group, a substituted carbocyclic group, a substituted heterocyclic group, a substituted aromatic group, and a substituted heteroaromatic group;
- R4 is selected from the group consisting of a monovalent hydrocarbon group, a heterogeneous group, a carbocyclic group, a heterocyclic group, an aromatic group, a heteroaromatic group, a substituted monovalent hydrocarbon group, a substituted heterogeneous group, a substituted carbocyclic group, a substituted heterocyclic group, a substituted aromatic group, and a substituted heteroaromatic group;
- X is selected from the group consisting of —C≡C—, a covalent bond, —CH═C═CH—, —CH═CH—, —CH═N—, —C(O)—, —C(O)Y—, —(CH2)n—, wherein n is 2 to 4, —CH2NH—, —CH2S—, and —CH2O—;
- Y is selected from the group consisting of a sulfur atom, an oxygen atom, and NH;
- and
- Z is selected from the group consisting of a carbocyclic group, a heterocyclic group, an aromatic group, a heteroaromatic group, a substituted carbocyclic group, a substituted heterocyclic group, a substituted aromatic group, and a substituted heteroaromatic group.
11 more elements
A mascara composition comprising:
- A) an active ingredient selected from the group consisting of a prostaglandin F analog having a structure selected from the group consisting of
- 113
- pharmaceutically acceptable salts and hydrates of the structures above;
- biohydrolyzable amides, esters, and imides of the structures above;
- optical isomers, diastereomers, and enantiomers of the structures above;
- and combinations thereof;
- wherein R1 is selected from the group consisting of C(O)OH, C(O)NHOH, C(O)OR3, CH2OH, S(O)2R3, C(O)NHR3, C(O)NHS(O)2R4, tetrazole, a cationic salt moiety, a pharmaceutically acceptable amine or ester comprising 2 to 13 carbon atoms, and a biometabolizable amine or ester comprising 2 to 13 atoms;
- R2 is selected from the group consisting of a hydrogen atom, a lower heterogenous group, and a lower monovalent hydrocarbon group;
- R3 is selected from the group consisting of a monovalent hydrocarbon group, a heterogeneous group, a carbocyclic group, a heterocyclic group, an aromatic group, a heteroaromatic group, a substituted monovalent hydrocarbon group, a substituted heterogeneous group, a substituted carbocyclic group, a substituted heterocyclic group, a substituted aromatic group, and a substituted heteroaromatic group;
- R4 is selected from the group consisting of a monovalent hydrocarbon group, a heterogeneous group, a carbocyclic group, a heterocyclic group, an aromatic group, a heteroaromatic group, a substituted monovalent hydrocarbon group, a substituted heterogeneous group, a substituted carbocyclic group, a substituted heterocyclic group, a substituted aromatic group, and a substituted heteroaromatic group;
- X is selected from the group consisting of —C≡C—, a covalent bond, —CH═C═CH—, —CH═CH—, —CH═N—, —C(O)—, —C(O)Y—, —(CH2)n—, wherein n is 2 to 4, —CH2NH—, —CH2S—, and —CH2O—;
- Y is selected from the group consisting of an oxygen atom, a sulfur atom, and NH;
- and
- Z is selected from the group consisting of a carbocyclic group, a heterocyclic group, an aromatic group, a heteroaromatic group, a substituted carbocyclic group. a substituted heterocyclic group, a substituted aromatic group, and a substituted heteroaromatic group;
- dd) a water-insoluble material,
- ee) a water-soluble, film-forming polymer,
- ff) a wax;
- o) a surfactant;
- gg) pigment;
- and
- s) a solvent.
18 more elements
A method for darkening and thickening hair comprising applying to growing hair and skin, a composition comprising:
- A) an active ingredient selected from the group consisting of a prostaglandin F analog having a structure selected from the group consisting of
- 114
- pharmaceutically acceptable salts and hydrates of the structures above;
- biohydrolyzable amides, esters, and imides of the structures above;
- optical isomers, diastereomers, and enantiomers of the structures above;
- and combinations thereof;
- wherein R1 is selected from the group consisting of C(O)OH, C(O)NHOH C(O)OR3, CH2OH, S(O)2R3, C(O)NHR3, C(O)NHS(O)2R4, tetrazole, a cationic salt moiety, a pharmaceutically acceptable amine or ester comprising 2 to 13 carbon atoms, and a biometabolizable amine or ester comprising 2 to 13 atoms;
- R2 is selected from the group consisting of a hydrogen atom, a lower heterogenous group, and a lower monovalent hydrocarbon group;
- R3 is selected from the group consisting of a monovalent hydrocarbon group, a heterogeneous group, a carbocyclic group, a heterocyclic group, an aromatic group, a heteroaromatic group, a substituted monovalent hydrocarbon group, a substituted heterogeneous group, a substituted carbocyclic group, a substituted heterocyclic group, a substituted aromatic group, and a substituted heteroaromatic group;
- R4 is selected from the group consisting of a monovalent hydrocarbon group, a heterogeneous group, a carbocyclic group, a heterocyclic group, an aromatic group, a heteroaromatic group, a substituted monovalent hydrocarbon group, a substituted heterogeneous group, a substituted carbocyclic group, a substituted heterocyclic group, a substituted aromatic group, and a substituted heteroaromatic group;
- X is selected from the group consisting of —C≡C—, a covalent bond, —CH═C═CH—, —CH═CH—, —CH═N—, —C(O)—, —C(O)Y—, —(CH2)n—, wherein n is 2 to 4, —CH2NH—, —CH2S—, and—CH2O—;
- Y is selected from the group consisting of an oxygen atom, a sulfur atom, and NH;
- and
- Z is selected from the group consisting of a carbocyclic group, a heterocyclic group, an aromatic group, a heteroaromatic group, a substituted carbocyclic group, a substituted heterocyclic group, a substituted aromatic group, and a substituted heteroaromatic group;
- and
- B) a carrier.
13 more elements
Dependencies are inferred from the claim text.